AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival (Q44007867)

28 November 2017

AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival (English)

1 reference

28 November 2017

Sarah S Bacus

1

1 reference

28 November 2017

Deborah A Altomare

2

1 reference

28 November 2017

Ljuba Lyass

3

1 reference

28 November 2017

Dot Mon Chin

4

1 reference

28 November 2017

Michael P Farrell

5

1 reference

28 November 2017

Katerina Gurova

6

1 reference

28 November 2017

Andrei Gudkov

7

1 reference

28 November 2017

Joseph R Testa

8

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

28 November 2017

1 reference

28 November 2017

21

1 reference

28 November 2017

3532-3540

1 reference

28 November 2017

22

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1205438

28 November 2017

0 references

cites work

Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Differentiation of cultured human breast cancer cells (AU-565 and MCF-7) associated with loss of cell surface HER-2/neu antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Regulation of cell death protease caspase-9 by phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Regulation of epidermal growth factor (EGF) receptor activity during the modulation of protein synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Cellular survival: a play in three Akts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Identification of heregulin, a specific activator of p185erbB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Heregulin regulation of Akt/protein kinase B in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Heregulin induces tyrosine phosphorylation of HER4/p180erbB4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

AKT plays a central role in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

Expression of erbB receptors and their ligands in breast cancer: implications to biological behavior and therapeutic response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

7 January 2021

Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

7 January 2021

NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

7 January 2021

The timing of treatment in breast cancer: gaps and delays in treatment can be harmful.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

7 January 2021

Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

7 January 2021

Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

7 January 2021

Recombinant Factor VIIa

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

7 January 2021

E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of IkappaB kinases and nuclear factor kappaB activities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

7 January 2021

ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205438

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1205438

1 reference

28 November 2017

1 reference